FOLH1 and prostate cancer: Between January 2014 and October 2024, our radiopharmacy performed 755 [68Ga]Ga-DOTATATE and 2,429 [68Ga]Ga-PSMA-11 syntheses, enabling PET scans for 1,636 and 5,892 patients, primarily for the evaluation of neuroendocrine tumors and prostate cancer, respectively.